Key result
Renal denervation safely provides sustained, adherence-independent blood pressure reductions in resistant hypertension.
Why the study?
Recent sham-controlled studies have shown consistent antihypertensive efficacy for renal denervation across a broad range of hypertensive patients, expanding beyond its original indication for severe resistant hypertension.
Does renal denervation reduce blood pressure in patients with resistant and uncontrolled hypertension?
Does renal denervation reduce blood pressure in patients with resistant and uncontrolled hypertension?
Renal denervation is a safe and effective non-pharmacological intervention that provides durable blood pressure reduction in patients with resistant hypertension, independent of patient adherence.
May support adjunctive use in resistant hypertension; leaves open large RCTs before practice change.
Renal denervation (RDN) is a catheter-based interventional approach that targets renal sympathetic nerves to modulate sympathetic overactivity, a key pathophysiological driver of resistant hypertension and associated cardiovascular complications. In contrast to pharmacological approaches, the therapeutic effect of RDN does not rely on patient adherence. Originally indicated for severe resistant hypertension, RDN has since shown consistent antihypertensive efficacy across a broad range of hypertensive patients in recent sham-controlled studies. In this review, we discuss the pathophysiological foundation underlying RDN, consolidate the current clinical evidence supporting its therapeutic efficacy, describe the spectrum of available ablation technologies, and evaluate its expanding applications in conditions driven by sympathetic overactivity.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a review in Resistant hypertension. Renal denervation vs. Sham procedure or optimal medical therapy was evaluated. Renal denervation provides safe, sustained, and adherence-independent blood pressure reductions in patients with resistant hypertension, supporting its repositioning as an evidence-based adjunctive treatment option.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: